Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neovasculgen in Peripheral Arterial Disease
NCT03068585Phase 3Completed
- Sponsor
- Artgen Biotech
- Start
- Feb 2010
- Primary completion
- Jun 2011
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 3 trial of neovasculgen in Peripheral Arterial Disease (PAD), sponsored by Artgen Biotech. Started Feb 2010; status: completed.
02
Drugs
neovasculgen
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT03068585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03068585.